小鸟体育

Innovation Zed and A.Menarini Diagnostics Enter Commercial Agreement for International Distribution of Innovative Insulin Pen 鈥業nsulCheck Connect鈥� Device

, an Irish medical technology company, and , a leading diagnostics company headquartered in Italy, and part of the Menarini Group, today announced an international partnership to commercialise the 鈥業nsulCheck Connect鈥� device developed by Innovation Zed.

鈥業nsulCheck Connect鈥� is an innovative insulin pen add-on device. It automatically collects essential usage data that informs insulin pen users of their injection history to assist them take control of their diabetes management. The 鈥業nsulCheck Connect鈥� device was specifically chosen to integrate within A.Menarini Diagnostics鈥� connected diabetes care platform.

With this agreement the two companies are forming a long-term partnership where A.Menarini Diagnostics will perform sales, marketing, training, and customer support, providing all necessary technical and clinical information for the correct use of the Insulin Pen 鈥業nsulCheck Connect鈥� device in regions around the globe including Europe.

Innovation Zed is headquartered at Nova小鸟体育, the Centre for New Ventures and Entrepreneurs at University College Dublin (小鸟体育).

鈥淲e are very pleased with this announcement,鈥� said, Dean Minnock, Director of Business Development and Third-Party Relationships, Innovation Zed.

鈥淭he relationships that A.Menarini Diagnostics has established with patients and healthcare providers in the diabetes community, and their extensive distribution expertise will positively position us to deliver to key international markets.鈥�

鈥淲ith this innovative insulin pen 鈥業nsulCheck Connect鈥� device, healthcare providers and patients will have a powerful tool to take under control the blood glucose levels and prevent diabetes complications,鈥� said Fabio Piazzalunga, General Manager and Global Head, A.Menarini Diagnostics.

鈥淭his agreement is part of our strategy to develop a portfolio of fully integrated innovative products, allowing an enhanced management of diabetes for healthcare providers and an improved quality of life for patients.鈥�

Dean Minnock, added, 鈥淎.Menarini Diagnostics has established fantastic relationships with patients and healthcare providers and has extensive distribution expertise to effectively utilise the 鈥業nsulCheck Connect鈥� device to greatly empower the diabetes community."

A.Menarini Diagnostics and Innovation Zed are also discussing terms to commercialise additional innovative systems to improve the quality of life for patients with diabetes.

ENDS

28 January 2020

For further information contact Mic茅al Whelan, Communications and Media Relations Manager, Nova小鸟体育, 小鸟体育 Research and Innovation, e: miceal.whelan@ucd.ie or t: +353 1 716 3712 or Dean Minnock, Director of Business Development and Third-Party Relationships, Innovation Zed, e: deanm@insulcheck.com.

Editors Notes

Innovation Zed Ltd is a medical technology company from Ireland, specialising connected health solutions that enable a step-up in user engagement, condition management and improved drug adherence for all injectable therapies.

Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnoses, meeting and exceeding the technological needs of Europe's most prominent healthcare professionals, improving and enhancing the quality of life of people with diabetes all over the world. A.Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today with presence in 136 countries throughout the world, it counts more than 17.000 employees and has a 2018 turnover of 鈧�3.667 billion.